Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Division of Pulmonary Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.
Swiss Med Wkly. 2022 Apr 14;152(15-16). doi: 10.4414/smw.2022.w30154. eCollection 2022 Apr 11.
Lung cancer is the leading cause of cancer-related deaths in Switzerland. Despite this, there is no lung cancer screening program in the country. In the United States, low-dose computed tomography (LDCT) lung cancer screening is partially established and endorsed by guidelines. Moreover, evidence is growing that screening reduces lung cancer-related mortality and this was recently shown in a large European randomized controlled trial. Implementation of a lung cancer screening program, however, is challenging and depends on many country-specific factors. The goal of this article is to outline a potential Swiss lung cancer screening program.
An exhaustive literature review on international screening models as well as interviews and site visits with international experts were initiated. Furthermore, workshops and interviews with national experts and stakeholders were conducted to share experiences and to establish the basis for a national Swiss lung cancer screening program.
General practitioners, pulmonologists and the media should be part of the recruitment process. Decentralisation of the screening might lead to a higher adherence rate. To reduce stigmatisation, the screening should be integrated in a "lung health check". Standardisation and a common quality level are mandatory. The PLCOm2012 risk calculation model with a threshold of 1.5% risk for developing cancer in the next six years should be used in addition to established inclusion criteria. Biennial screening is preferred. LUNG RADS and NELSON+ are applied as classification models for lung nodules.
Based on data from recent studies, literature research, a health technology assessment, the information gained from this project and a pilot study the Swiss Interest Group for lung cancer screening (CH-LSIG) recommends the timely introduction of a systematic lung cancer screening program in Switzerland. The final decision is for the Swiss Cancer Screening Committee to make.
肺癌是瑞士癌症相关死亡的主要原因。尽管如此,该国仍没有肺癌筛查计划。在美国,低剂量计算机断层扫描 (LDCT) 肺癌筛查已部分确立并得到指南的认可。此外,越来越多的证据表明筛查可降低肺癌相关死亡率,最近一项大型欧洲随机对照试验也证明了这一点。然而,实施肺癌筛查计划具有挑战性,取决于许多特定于国家的因素。本文的目的是概述瑞士潜在的肺癌筛查计划。
对国际筛查模型进行了全面的文献回顾,并对国际专家进行了访谈和实地考察。此外,还与国家专家和利益相关者进行了研讨会和访谈,以分享经验并为瑞士国家肺癌筛查计划奠定基础。
全科医生、肺科医生和媒体应成为招募过程的一部分。筛查的去中心化可能会导致更高的依从率。为了减少污名化,筛查应纳入“肺部健康检查”。标准化和共同的质量水平是强制性的。应使用 PLCOm2012 风险计算模型,其风险阈值为未来六年内癌症发病率为 1.5%,此外还应使用既定的纳入标准。两年一次的筛查是首选。LUNG RADS 和 NELSON+ 用作肺结节的分类模型。
基于最近研究的数据、文献研究、卫生技术评估、从该项目获得的信息和一项试点研究,瑞士肺癌筛查兴趣小组 (CH-LSIG) 建议瑞士及时引入系统性肺癌筛查计划。最终决定由瑞士癌症筛查委员会做出。